NEWS – PrimeVigilance adds specialist pharmacoepidemiology services

We do this by providing systematic risk minimization and faster insights into the safety and effectiveness of drugs to ensure patient safety and to meet evolving regulatory demands.
“The Primary driver for the need of pharmacoepidemiology is increased enforcement by regulators worldwide to generate pharmacovigilance real-world evidence,” says Dr Jan Petracek, CEO of PrimeVigilance and COO of Ergomed group.
PrimeVigilance’s new Head of Pharmacoepidemiology and Risk Management, Dr Michael Forstner, a well-known expert in this field, together with the team he has assembled, will be focusing on providing our clients with full services in these areas.
For more information, please visit our website new Pharmacoepidemiology section
or feel free to contact us at marketing@primevigilance.com